Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL77789 | 1.00 | DGAT1 (0.40) | DGAT1ALDH1A1HPGDUSP2SMN1; SMN2 | |
| SCHEMBL77788 | 1.00 | DGAT1 (0.40) | DGAT1ALDH1A1HPGDUSP2SMN1; SMN2 | |
| SCHEMBL1542636 | 0.89 | DGAT1 (0.34) | DGAT1ALDH1A1HPGD | |
| SCHEMBL260377 | 0.89 | DGAT1 (0.34) | DGAT1ALDH1A1HPGD | |
| SCHEMBL904794 | 0.89 | DGAT1 (0.34) | DGAT1ALDH1A1HPGD | |
| SCHEMBL15843648 | 0.89 | DGAT1 (0.44) | DGAT1ALDH1A1HPGDTDP1CA1 | |
| SCHEMBL20278337 | 0.89 | DGAT1 (0.34) | DGAT1ALDH1A1HPGD | |
| SCHEMBL15843647 | 0.89 | DGAT1 (0.44) | DGAT1ALDH1A1HPGDTDP1CA1 | |
| SCHEMBL19023277 | 0.87 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL19028120 | 0.87 | DGAT1 (0.33) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078133-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2026-03-19 | — | — | US | disclosed |
| EP-4694980-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS INHIBITORS OF NLRP3 | Takeda Pharmaceutical Company Limited (JP) | 2026-02-18 | — | — | EP | disclosed |
| US-12251387-B2 | Substituted quinoxalines and benzo[c][1,2,5]oxadiazoles as DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-03-18 | — | — | US | disclosed |
| EP-3740479-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2024-11-20 | — | — | EP | disclosed |
| US-12121524-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-10-22 | — | — | US | disclosed |
| WO-2024214046-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS INHIBITORS OF NLRP3 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-10-17 | — | — | WO | disclosed |
| US-20240245658-A1 | TAAR1 AND SEROTONIN MODULATORS, AND PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2024-07-25 | — | — | US | disclosed |
| CN-111741955-B | DNA-PK inhibitors | 沃泰克斯药物股份有限公司 | 2024-02-23 | — | — | CN | disclosed |
| EP-4319738-A1 | TAAR1 AND SEROTONIN MODULATORS, AND PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| US-20230277547-A1 | SUBSTITUTED QUINOXALINE DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-09-07 | — | — | US | disclosed |
| WO-2010116176-A1 | PYRAZOLO [4, 5-E] PYRIMIDINE DERIVATIVE AND ITS USE TO TREAT DIABETES AND OBESITY | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | WO | disclosed |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| WO-2010015849-A2 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-02-11 | — | — | WO | disclosed |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-05 | — | — | US | disclosed |
| US-7598422-B2 | Production of chirally pure amino alcohol intermediates, derivatives thereof, and uses thereof | WYETH (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090069294-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-03-12 | — | — | US | disclosed |
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | METHYLGENE INC. | 2008-11-13 | — | — | US | disclosed |
| US-7405280-B2 | Chromogenic substances and use thereof for the determination of carboxypeptidase activities | DIAGNOSTICA STAGO (FR) | 2008-07-29 | — | — | US | disclosed |
| US-7405280-B2 | Chromogenic substances and use thereof for the determination of carboxypeptidase activities | DIAGNOSTICA STAGO (FR) | 2008-07-29 | — | — | US | disclosed |
| US-20070249869-A1 | Production of chirally pure amino alcohol intermediates, derivatives thereof, and uses thereof | WYETH (US) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069294-A1 | Organic Compounds | XIAP, BAX, MCL1 | DGAT1 2387/4885ALDH1A1 1673/4885HPGD 2185/4885 |
| US-20230277547-A1 | SUBSTITUTED QUINOXALINE DNA-PK INHIBITORS | DTYMK, POLK, TOP1 | DGAT1 4169/4885ALDH1A1 2519/4885HPGD 484/4885 |
| US-20260078133-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | DGAT1 2503/4885ALDH1A1 3635/4885HPGD 4265/4885 |
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | CARM1, PRMT1, PRMT3 | DGAT1 4103/4885ALDH1A1 2119/4885HPGD 2834/4885 |
| US-20240245658-A1 | TAAR1 AND SEROTONIN MODULATORS, AND PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | TAAR1, TAAR5, NPY1R | DGAT1 4528/4885ALDH1A1 1200/4885HPGD 2608/4885 |
| US-12121524-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | DGAT1 4221/4885ALDH1A1 3073/4885HPGD 1083/4885 |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | GCK, GCKR, GPR119 | DGAT1 931/4885ALDH1A1 1918/4885HPGD 694/4885 |
| US-12251387-B2 | Substituted quinoxalines and benzo[c][1,2,5]oxadiazoles as DNA-PK inhibitors | TOP1, TOP2A, TOP2B | DGAT1 4761/4885ALDH1A1 1023/4885HPGD 558/4885 |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | SPINT2, DNPEP, PRSS1 | DGAT1 2685/4885ALDH1A1 1604/4885HPGD 2979/4885 |
| US-20070249869-A1 | Production of chirally pure amino alcohol intermediates, derivatives thereof, and uses thereof | ADH1C, ADH1A, ACMSD | DGAT1 656/4885ALDH1A1 51/4885HPGD 1986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.